



## Targeted Nanotherapy in Cancer Disease

Guest Editors:

**Prof. Dr. Donatella Paolino**

Department of Experimental and  
Clinical Medicine, University  
Magna Graecia of Catanzaro,  
88100 Catanzaro, Italy

**Dr. Ana Isabel Fraguas-  
Sánchez**

Department of Pharmaceutics  
and Food Technology, Faculty of  
Pharmacy, Complutense  
University of Madrid, 28040  
Madrid, Spain

**Dr. Cristina Martin-Sabroso**

Department of Pharmaceutics  
and Food Technology, Faculty of  
Pharmacy, Complutense  
University of Madrid, 28040  
Madrid, Spain

Deadline for manuscript  
submissions:

**closed (20 January 2022)**

### Message from the Guest Editors

Dear Colleagues,

Despite all the continuous efforts, cancer disease is a leading cause of death worldwide. In the last decades, the development of targeted therapeutics has revolutionized cancer therapy, with numerous formulations based on monoclonal antibodies, small molecule enzyme inhibitors, and recombinant proteins approved or under clinical trials for the treatment of several neoplasms. In certain types of carcinomas and advanced stages of the disease, chemotherapy constitutes a major treatment strategy, showing, in general, high toxicity. Their selective delivery to cancer cells may resolve this problem and increase the anticancer efficacy. In this way, several strategies have been used for this purpose, including the development of monoclonal-antibodies drug conjugates or the use of nanocarriers coated with ligands specifically recognized by cancer cells.

In the present Special Issue, studies reporting original data or updated literature reviews concerning targeted chemonanotherapy are welcome.

Prof. Dr. Donatella Paolino  
Prof. Dr. Ana Isabel Fraguas-Sánchez  
Dr. Cristina Martin-Sabroso  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Patrick J. Sinko**

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma